Your browser doesn't support javascript.
loading
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Jakubowiak, Andrzej; Offidani, Massimo; Pégourie, Brigitte; De La Rubia, Javier; Garderet, Laurent; Laribi, Kamel; Bosi, Alberto; Marasca, Roberto; Laubach, Jacob; Mohrbacher, Ann; Carella, Angelo Michele; Singhal, Anil K; Tsao, L Claire; Lynch, Mark; Bleickardt, Eric; Jou, Ying-Ming; Robbins, Michael; Palumbo, Antonio.
Afiliação
  • Jakubowiak A; Myeloma Program, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL;
  • Offidani M; Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy;
  • Pégourie B; Centre Hospitalier Universitaire de Grenoble-Hôpital Albert Michallon, Grenoble, France;
  • De La Rubia J; Hospital Universitario Doctor Peset and Universidad Católica "San Vicente Mártir," Valencia, Spain;
  • Garderet L; Service d'hématologie, Hôpital Saint Antoine, Paris, France;
  • Laribi K; Department of Hematology, Centre Hospitalier, Le Mans, France;
  • Bosi A; Department of Hematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy;
  • Marasca R; Department of Hematology, Azienda Ospedaliera Universitaria-Policlinico di Modena, Modena, Italy;
  • Laubach J; Department of Hematology/Oncology, Dana-Farber Cancer Institute, Boston, MA;
  • Mohrbacher A; Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA;
  • Carella AM; Hematology Unit, Istituto di Ricovero e Cura a Carattere Scientifico San Martino-Istituto Scientifico Tumori, Genoa, Italy;
  • Singhal AK; Statistics, AbbVie Biotherapeutics Inc, Redwood City, CA;
  • Tsao LC; Statistics, AbbVie Biotherapeutics Inc, Redwood City, CA;
  • Lynch M; Oncology Clinical Development, Bristol-Myers Squibb, Wallingford, CT;
  • Bleickardt E; Oncology Clinical Development, Bristol-Myers Squibb, Wallingford, CT;
  • Jou YM; Global Biometric Sciences, Bristol-Myers Squibb, Hopewell, NJ;
  • Robbins M; Exploratory Clinical and Translational Research-Oncology, Bristol-Myers Squibb, Princeton, NJ; and.
  • Palumbo A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
Blood ; 127(23): 2833-40, 2016 06 09.
Article em En | MEDLINE | ID: mdl-27091875
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Medicamentos Antineoplásicos / Anticorpos Monoclonais Humanizados / Bortezomib / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Medicamentos Antineoplásicos / Anticorpos Monoclonais Humanizados / Bortezomib / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2016 Tipo de documento: Article